Treatment with Horizon Therapeutics’ Uplizna (inebilizumab-cdon) was found safe and effective at reducing the frequency of attacks in African-American adults with neuromyelitis optica spectrum disorder (NMOSD), according to a retrospective analysis of the N-MOmentum clinical trial. These findings were presented in a poster at the 15th World Congress…
B-cells
Recent Posts
- Bladder dysfunction: The NMOSD plot twist that nobody wants
- Older age at NMOSD onset may raise disease relapse risk
- Exploring the therapeutic benefits of mobile gaming
- Blood test for natural killer cells could improve NMOSD diagnosis: Study
- NMOSD: A full-time job with no pay, no vacation time, and lousy benefits